Assess whether working capital should be a walk-away (3b16de)

SITUATION Regulatory-approval critical-path calendar arrived with a QoE that cannot tie revenue to bank cash. Customer-contract risk reviewer in a family-office reviewing a manufacturing target still has an evidence gap on whether working capital should be a walk-away.

DECISION Customer-contract risk reviewer in a family-office reviewing a manufacturing target must choose Proceed / Reprice / Walk / Hold using regulatory-approval critical-path calendar after a QoE that cannot tie revenue to bank cash.

HYPOTHESES TO TEST 1. A QoE that cannot tie revenue to bank cash is noise around an already-controlled Legal, IP, and Regulatory process in a family-office reviewing a manufacturing target, given regulatory-approval critical-path calendar. 2. A QoE that cannot tie revenue to bank cash is the event in regulatory-approval critical-path calendar that forces Proceed for customer-contract risk reviewer under M&A Due Diligence. 3. Regulatory-approval critical-path calendar shows a one-file miss after a QoE that cannot tie revenue to bank cash, not a Legal, IP, and Regulatory program failure. 4. Regulatory-approval critical-path calendar cannot decide working capital should be yet after a QoE that cannot tie revenue to bank cash; hold is the only M&A Due Diligence close a family-office reviewing a manufacturing target can defend.

ANALYSIS REQUIRED 1. Tie quality-of-earnings, working-capital, and contingent items in regulatory-approval critical-path calendar to working capital should be. 2. Name the document customer-contract risk reviewer still needs before signing. 3. Test whether a QoE that cannot tie revenue to bank cash is a diligence gap, a price chip, or a walk-away. 4. For this M&A Due Diligence Legal, IP, and Regulatory file, read regulatory-approval critical-path calendar against a QoE that cannot tie revenue to bank cash and write the one fact that would move working capital should be for customer-contract risk reviewer.

RECOMMENDATION Choose Proceed / Reprice / Walk / Hold on this M&A Due Diligence / Legal, IP, and Regulatory packet (regulatory-approval critical-path calendar after a QoE that cannot tie revenue to bank cash). The follow-on Legal, IP, and Regulatory action is what customer-contract risk reviewer does next: implement the option, assign an owner, and log the missing fact.

COMMAND RETURNS - Bottom-line M&A Due Diligence option on working capital should be, then the evidence in regulatory-approval critical-path calendar, then the action for customer-contract risk reviewer - Hypothesis scorecard against regulatory-approval critical-path calendar: supported / rejected / untestable - Owner and next date for customer-contract risk reviewer in a family-office reviewing a manufacturing target - What changes working capital should be if a QoE that cannot tie revenue to bank cash is later withdrawn